pdb_id: "5LF3"
viewer:
  width: 800
  height: 600
visualization:
  chain_style: 
    stick: {}
  residue_style:
    stick: 
      colorscheme: "cyanCarbon"
ligand: "BOR"      # Main drug/ligand to map

binding_site_detection:
  enabled: true    # Switch for biopython residue mapping
  cutoff_angstrom: 5.0

mutations:
  - chain: K
    resnum: 45
    mutation: A45T
    effect: resistance
  - chain: K
    resnum: 49
    mutation: C49W
    effect: unknown

therapies:
  - name: Bortezomib
    pdb_ligand: BOR
    clinical_phase: Approved
    mm_relevance: High
    resistance_mutations: [A45T, C49W]
  - name: Carfilzomib
    pdb_ligand: ...
    clinical_phase: Approved
    mm_relevance: High
    resistance_mutations: [...]

pathways:
  - name: "Proteasome pathway"
    kegg_id: "hsa03050"
    reactome_id: "R-HSA-174084"

literature:
  - doi: "10.1126/science.aaf8993"
    pmid: "27493187"
    title: "The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design."
